- Home
- EQBK vs MLYS Comparison
EQBK vs MLYS Comparison
Compare EQBK & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQBK
- MLYS
- Stock Information
- Founded
- EQBK 2002
- MLYS 2019
- Country
- EQBK United States
- MLYS United States
- Employees
- EQBK N/A
- MLYS N/A
- Industry
- EQBK Major Banks
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- EQBK Finance
- MLYS Health Care
- Exchange
- EQBK Nasdaq
- MLYS Nasdaq
- Market Cap
- EQBK 750.4M
- MLYS 634.6M
- IPO Year
- EQBK 2015
- MLYS 2023
- Fundamental
- Price
- EQBK $43.12
- MLYS $9.24
- Analyst Decision
- EQBK Hold
- MLYS Strong Buy
- Analyst Count
- EQBK 4
- MLYS 2
- Target Price
- EQBK $44.50
- MLYS $30.00
- AVG Volume (30 Days)
- EQBK 84.6K
- MLYS 266.6K
- Earning Date
- EQBK 01-22-2025
- MLYS 11-11-2024
- Dividend Yield
- EQBK 1.25%
- MLYS N/A
- EPS Growth
- EQBK N/A
- MLYS N/A
- EPS
- EQBK 1.12
- MLYS N/A
- Revenue
- EQBK $157,755,000.00
- MLYS N/A
- Revenue This Year
- EQBK N/A
- MLYS N/A
- Revenue Next Year
- EQBK $6.05
- MLYS N/A
- P/E Ratio
- EQBK $38.46
- MLYS N/A
- Revenue Growth
- EQBK N/A
- MLYS N/A
- 52 Week Low
- EQBK $30.44
- MLYS $8.28
- 52 Week High
- EQBK $50.85
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- EQBK 50.11
- MLYS 32.12
- Support Level
- EQBK $39.26
- MLYS $8.60
- Resistance Level
- EQBK $43.27
- MLYS $9.97
- Average True Range (ATR)
- EQBK 1.07
- MLYS 0.88
- MACD
- EQBK 0.28
- MLYS -0.31
- Stochastic Oscillator
- EQBK 85.02
- MLYS 13.25
About EQBK Equity Bancshares Inc.
Equity Bancshares Inc is a bank holding company. The company's operation involves the delivery of loan and deposit products to customers. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.